David J Irwin1,2, Alberto Lleó3, Sharon X Xie4, Corey T McMillan2, David A Wolk5, Edward B Lee6, Viviana M Van Deerlin1, Leslie M Shaw1, John Q Trojanowski1, Murray Grossman2. 1. Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 2. Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 3. Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Barcelona, Spain and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Barcelona, Spain. 4. Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 5. Alzheimer's Disease Center, Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 6. Translational Neuropathology Lab, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Abstract
OBJECTIVE: To test the hypotheses that (1) antemortem cerebrospinal fluid (CSF) tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration (FTLD) and (2) tauopathy patients have higher phosphorylated-tau levels compared to transactivation response element DNA-binding protein 43 (TDP-43) proteinopathy patients while accounting for Alzheimer's disease (AD) copathology. METHODS: Patients had autopsy-confirmed FTLD with tauopathy (n = 31), TDP-43 proteinopathy (n = 49), or AD (n = 26) with antemortem CSF. CSF tau levels were compared between groups and correlated with digital histology measurement of postmortem tau pathology averaged from three cerebral regions (angular gyrus, mid-frontal cortex, and anterior cingulate gyrus). Multivariate linear regression tested the association of ante mortem CSF tau levels with postmortem tau pathology adjusting for demographics. RESULTS: Multivariate regression found an independent association of ante mortem CSF phosphorylated tau levels with postmortem cerebral tau pathology in FTLD (Beta = 1.3; 95% confidence interval = 0.2-2.4; p < 0.02). After excluding patients with coincident AD-associated tau pathology accompanying sporadic FTLD, we found lower CSF phosphorylated tau levels in the TDP-43 group (median = 7.4pg/ml; interquartile range [IQR] = 6.0, 12.3; n = 26) compared to the tauopathy group (median = 12.5pg/ml; IQR = 10.7, 15.0; n = 23; Z = 2.6; p < 0.01). INTERPRETATION: CSF phosphorylated-tau levels are positively associated with cerebral tau burden in FTLD. In vivo detection of AD copathology in sporadic FTLD patients may help stratify clinical cohorts with pure neuropathology in which low CSF phosphorylated-tau levels may have diagnostic utility to distinguish TDP-43 proteinopathy from tauopathy. Autopsy-confirmed samples are critical for FTLD biomarker development and validation. Ann Neurol 2017;82:247-258.
OBJECTIVE: To test the hypotheses that (1) antemortem cerebrospinal fluid (CSF) tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration (FTLD) and (2) tauopathypatients have higher phosphorylated-tau levels compared to transactivation response element DNA-binding protein 43 (TDP-43) proteinopathypatients while accounting for Alzheimer's disease (AD) copathology. METHODS:Patients had autopsy-confirmed FTLD with tauopathy (n = 31), TDP-43 proteinopathy (n = 49), or AD (n = 26) with antemortem CSF. CSF tau levels were compared between groups and correlated with digital histology measurement of postmortem tau pathology averaged from three cerebral regions (angular gyrus, mid-frontal cortex, and anterior cingulate gyrus). Multivariate linear regression tested the association of ante mortem CSF tau levels with postmortem tau pathology adjusting for demographics. RESULTS: Multivariate regression found an independent association of ante mortem CSF phosphorylated tau levels with postmortem cerebral tau pathology in FTLD (Beta = 1.3; 95% confidence interval = 0.2-2.4; p < 0.02). After excluding patients with coincident AD-associated tau pathology accompanying sporadic FTLD, we found lower CSF phosphorylated tau levels in the TDP-43 group (median = 7.4pg/ml; interquartile range [IQR] = 6.0, 12.3; n = 26) compared to the tauopathy group (median = 12.5pg/ml; IQR = 10.7, 15.0; n = 23; Z = 2.6; p < 0.01). INTERPRETATION: CSF phosphorylated-tau levels are positively associated with cerebral tau burden in FTLD. In vivo detection of AD copathology in sporadic FTLDpatients may help stratify clinical cohorts with pure neuropathology in which low CSF phosphorylated-tau levels may have diagnostic utility to distinguish TDP-43 proteinopathy from tauopathy. Autopsy-confirmed samples are critical for FTLD biomarker development and validation. Ann Neurol 2017;82:247-258.
Authors: Carlo Wilke; Christian Deuschle; Tim W Rattay; Walter Maetzler; Matthis Synofzik Journal: Neurobiol Aging Date: 2014-10-18 Impact factor: 4.673
Authors: Anne M Fagan; Leslie M Shaw; Chengjie Xiong; Hugo Vanderstichele; Mark A Mintun; John Q Trojanowski; Els Coart; John C Morris; David M Holtzman Journal: Arch Neurol Date: 2011-05-09
Authors: M L Schmidt; T Schuck; S Sheridan; M P Kung; H Kung; Z P Zhuang; C Bergeron; J S Lamarche; D Skovronsky; B I Giasson; V M Lee; J Q Trojanowski Journal: Am J Pathol Date: 2001-09 Impact factor: 4.307
Authors: David J Irwin; Matthew D Byrne; Corey T McMillan; Felicia Cooper; Steven E Arnold; Edward B Lee; Vivianna M Van Deerlin; Sharon X Xie; Virginia M-Y Lee; Murray Grossman; John Q Trojanowski Journal: J Histochem Cytochem Date: 2015-11-04 Impact factor: 2.479
Authors: Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling Journal: Ann Neurol Date: 2015-12-15 Impact factor: 10.422
Authors: David J Irwin; Johannes Brettschneider; Corey T McMillan; Felicia Cooper; Christopher Olm; Steven E Arnold; Vivianna M Van Deerlin; William W Seeley; Bruce L Miller; Edward B Lee; Virginia M-Y Lee; Murray Grossman; John Q Trojanowski Journal: Ann Neurol Date: 2015-12-25 Impact factor: 10.422
Authors: Jon B Toledo; Vivianna M Van Deerlin; Edward B Lee; EunRan Suh; Young Baek; John L Robinson; Sharon X Xie; Jennifer McBride; Elisabeth M Wood; Theresa Schuck; David J Irwin; Rachel G Gross; Howard Hurtig; Leo McCluskey; Lauren Elman; Jason Karlawish; Gerard Schellenberg; Alice Chen-Plotkin; David Wolk; Murray Grossman; Steven E Arnold; Leslie M Shaw; Virginia M-Y Lee; John Q Trojanowski Journal: Alzheimers Dement Date: 2013-08-24 Impact factor: 21.566
Authors: Jennifer L Whitwell; Stephen D Weigand; Bradley F Boeve; Matthew L Senjem; Jeffrey L Gunter; Mariely DeJesus-Hernandez; Nicola J Rutherford; Matthew Baker; David S Knopman; Zbigniew K Wszolek; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Rosa Rademakers; Clifford R Jack; Keith A Josephs Journal: Brain Date: 2012-03 Impact factor: 13.501
Authors: Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici Journal: Acta Neuropathol Date: 2006-08-12 Impact factor: 17.088
Authors: Alberto Lleó; David J Irwin; Ignacio Illán-Gala; Corey T McMillan; David A Wolk; Edward B Lee; Vivianna M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman Journal: JAMA Neurol Date: 2018-06-01 Impact factor: 18.302
Authors: Garrett S Gibbons; Rachel A Banks; Bumjin Kim; Lakshmi Changolkar; Dawn M Riddle; Susan N Leight; David J Irwin; John Q Trojanowski; Virginia M Y Lee Journal: J Neuropathol Exp Neurol Date: 2018-03-01 Impact factor: 3.685
Authors: Daniel Alcolea; David J Irwin; Ignacio Illán-Gala; Laia Muñoz; Jordi Clarimón; Corey T McMillan; Juan Fortea; Rafael Blesa; Edward B Lee; John Q Trojanowski; Murray Grossman; Alberto Lleó Journal: J Neurol Neurosurg Psychiatry Date: 2018-10-08 Impact factor: 10.154
Authors: Jiasi Vicky Zhang; David J Irwin; Kaj Blennow; Henrik Zetterberg; Edward B Lee; Leslie M Shaw; Katya Rascovsky; Lauren Massimo; Corey T McMillan; Alice Chen-Plotkin; Lauren Elman; Virginia M-Y Lee; Leo McCluskey; Jon B Toledo; Daniel Weintraub; David Wolk; John Q Trojanowski; Murray Grossman Journal: Neurol Clin Pract Date: 2021-04
Authors: Ignacio Illán-Gala; Alberto Lleo; Anna Karydas; Adam M Staffaroni; Henrik Zetterberg; Rajeev Sivasankaran; Lea T Grinberg; Salvatore Spina; Joel H Kramer; Eliana M Ramos; Giovanni Coppola; Renaud La Joie; Gil D Rabinovici; David C Perry; Maria Luisa Gorno-Tempini; William W Seeley; Bruce L Miller; Howard J Rosen; Kaj Blennow; Adam L Boxer; Julio C Rojas Journal: Neurology Date: 2020-11-16 Impact factor: 11.800